OncoCyte (OCX) Stock Chart & Stock Price History $2.16 -0.03 (-1.37%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends OncoCyte Stock Price Performance 5 Day Performance-1.37%1 Month Performance-14.62%3 Month Performance-27.27%6 Month Performance-18.18%Year-To-Date Performance-13.60%1 Year Performance-14.29% Receive OCX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You See Trump’s Bombshell Exec. Order 001? (Ad)Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. OCX Stock Chart for Thursday, December, 26, 2024 OCX Chart by TradingView OncoCyte Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization12/25/2024$2.16$2.16$2.21$2.1521,123 shs$36.36 million12/24/2024$2.19$2.16-1.37%$2.21$2.1521,123 shs$36.36 million12/23/2024$2.19$2.19$2.25$2.199,992 shs$36.87 million12/20/2024$2.21$2.19-0.90%$2.27$2.1578,197 shs$36.87 million12/19/2024$2.20$2.21+0.45%$2.28$2.18138,346 shs$37.21 million12/18/2024$2.21$2.20-0.45%$2.36$2.1851,097 shs$37.04 million Get the Latest News and Ratings for OCX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. 12/17/2024$2.22$2.21-0.45%$2.31$2.1916,734 shs$37.19 million12/16/2024$2.32$2.22-4.31%$2.32$2.2223,168 shs$37.36 million12/13/2024$2.39$2.32-2.93%$2.48$2.3131,568 shs$39.05 million12/12/2024$2.39$2.39$2.47$2.348,258 shs$40.24 million12/11/2024$2.50$2.39-4.40%$2.49$2.3313,478 shs$40.24 million12/10/2024$2.46$2.50+1.63%$2.54$2.44162,567 shs$42.09 million12/09/2024$2.45$2.46+0.41%$2.54$2.43242,026 shs$41.40 million12/06/2024$2.30$2.45+6.52%$2.50$2.3544,470 shs$41.25 million12/05/2024$2.39$2.30-3.77%$2.44$1.98607,167 shs$38.71 million12/04/2024$2.40$2.39-0.42%$2.45$2.33207,594 shs$40.22 million12/03/2024$2.45$2.40-2.04%$2.48$2.3820,065 shs$40.39 million12/02/2024$2.44$2.45+0.41%$2.48$2.3438,220 shs$41.25 million11/29/2024$2.44$2.44+0.21%$2.50$2.32329,084 shs$41.08 million11/28/2024$2.44$2.44$2.59$2.00286,368 shs$40.98 million11/27/2024$2.53$2.44-3.75%$2.59$2.00286,362 shs$40.98 million11/26/2024$2.64$2.53-4.17%$2.79$2.5071,369 shs$42.58 million11/25/2024$2.71$2.64-2.58%$2.74$2.628,526 shs$44.43 million Related Companies FitLife Brands Stock Price Chart Biomea Fusion Stock Price Chart InflaRx Stock Price Chart Nanobiotix Stock Price Chart Aligos Therapeutics Stock Price Chart Telomir Pharmaceuticals Stock Price Chart Puma Biotechnology Stock Price Chart Instil Bio Stock Price Chart Vaxart Stock Price Chart XBiotech Stock Price Chart Receive OCX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:OCX) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
